title: Subconjunctival bevacizumab for corneal neovascularization in herpetic stromal keratitis.
abstract: OBJECTIVE
  To report an 81-year-old woman with corneal neovascularization secondary to herpetic stromal keratitis treated with subconjunctival bevacizumab and to discuss the role of this novel antiangiogenic treatment.
  
  
  METHODS
  Case report and review of medical literature.
  
  
  RESULTS
  A dramatic regression of corneal vessels was observed 1 week after the injection. After a 3-month follow-up, there was no recurrence of corneal revascularization.
  
  
  CONCLUSIONS
  Bevacizumab may be a valid complementary treatment in patients with corneal neovascularization caused by herpetic stromal keratitis.
authors.affiliation: Centrovision Mendoza, National University of Cuyo, Mendoza, Argentina. macarras73@gmail.com
authors.forename: María Alejandra
authors.initials: MA
authors.lastname: Carrasco
mesh_terms: D000212:Acyclovir / Q000627:therapeutic use; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D016510:Corneal Neovascularization / Q000188:drug therapy* / Q000209:etiology; D003319:Corneal Stroma / Q000821:virology; D005260:Female; D006801:Humans; D016849:Keratitis, Herpetic / Q000150:complications* / Q000188:drug therapy; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; D000212:Acyclovir